Status: Recruiting
Study of EV for Recurrent Endometrial Carcinoma
This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy. The goal is to see how well the drug works and how safe it is. Patients will be treated for up to one year and followed over time to monitor their health and response to the treatment.
Participants needed: 12
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: William BradleyUpdated: Jul 13, 2026Locations: 1
Eligibility criteria
Female patient of age ≥18 years. [+22]
Diagnosis of endometrial sarcoma (leiomyosarcoma, endometrial stromal sarcoma, h... [+16]